Literature DB >> 1280571

Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

J E Frampton1, R N Brogden, H D Langtry, M M Buckley.   

Abstract

Cefpodoxime proxetil is an orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third generation cephalosporin, cefpodoxime. Cefpodoxime is stable towards the most commonly found plasmid-mediated beta-lactamases and the drug has a broad spectrum of antibacterial activity encompassing both Gram-negative and Gram-positive bacteria, rendering it a possible option for empirical use in a wide range of community acquired infections in both adult and paediatric patients. The extended plasma half-life of cefpodoxime (1.9 to 3.7 h) permits twice daily administration. In comparative trials, twice daily cefpodoxime proxetil (dose equivalent cefpodoxime 100 to 400 mg) was as effective as a 3- to 4-times daily regimen of phenoxymethylpenicillin in pharyngotonsillitis, as well as thrice daily amoxicillin (with or without clavulanic acid) or cefaclor against infections of the ear, the upper and lower respiratory tract, the urinary tract and those of the skin and soft tissues. The latter reflects the enhanced antistaphylococcal activity of cefpodoxime, which distinguishes it from other orally active third generation cephalosporins such as cefixime. Most notably, an oral regimen of cefpodoxime proxetil was as efficacious as parenterally administered ceftriaxone for the treatment of bronchopneumonia in hospitalised patients at risk due to the presence of underlying diseases, addictions or advancing age. A single oral dose of cefpodoxime was also as efficacious as ceftriaxone in uncomplicated anogenital gonococcal infections. Cefpodoxime proxetil is generally well tolerated, with mild to moderate gastrointestinal disturbances occurring in 4 to 15% of patients treated with therapeutic doses. Thus, a convenient twice daily oral regimen of cefpodoxime proxetil can be prescribed as an effective alternative to established beta-lactam therapies in the empirical outpatient treatment of infections of the respiratory and urinary tracts as well as those of the skin and soft tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280571     DOI: 10.2165/00003495-199244050-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  64 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  Clinical trials of cefpodoxime proxetil suspension in paediatrics.

Authors:  R Fujii
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.

Authors:  L Couraud; J M Andrews; H Lecoeur; E Sultan; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

4.  Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.

Authors:  P Gehanno; J M Andrews; F Ichou; E Sultan; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

5.  Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.

Authors:  D Tremblay; A Dupront; C Ho; D Coussediere; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

6.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.

Authors:  R D Schaadt; B H Yagi; G E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Antibacterial activity of cefpodoxime against Branhamella catarrhalis.

Authors:  T Takenouchi; T Nishino
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 1.955

9.  Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients.

Authors:  C Backhouse; A Wade; P Williamson; D Tremblay; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

10.  Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media.

Authors:  P M Mendelman; M A Del Beccaro; S E McLinn; W M Todd
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

View more
  12 in total

Review 1.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

2.  Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.

Authors:  M W Garrison; C L Malone; J E Eiland
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 3.  Rational prescribing of antibacterials in ambulatory children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 4.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 5.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice study.

Authors:  A Pelc; H Portier; P Gehanno; S Fiessinger; F Ichou
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

7.  Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.

Authors:  Demetra Kavatha; Helen Giamarellou; Zoe Alexiou; Nickolas Vlachogiannis; Stavroula Pentea; Thomas Gozadinos; Garyphalia Poulakou; Agissilaos Hatzipapas; George Koratzanis
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 8.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

9.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

10.  Cefpodoxime: pharmacokinetics and therapeutic uses.

Authors:  Krishan Chugh; Shruti Agrawal
Journal:  Indian J Pediatr       Date:  2003-03       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.